SCHEMBL25234886

SCHEMBL25234886

COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1COc1ccc(F)cc1F

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.79
▸ KMT2A Q03164 9/20 0.79
▸ ALDH1A1 P00352 5/20 0.79
▸ LMNA P02545 4/20 0.79
▸ KDM4E B2RXH2 2/20 0.79
▸ MAPT P10636 3/20 0.73
▸ THRB P10828 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ POLB P06746 2/20 0.64
▸ HPGD P15428 1/20 0.64
▸ CTSL P07711 2/20 0.57
▸ CXCL12 P48061 1/20 0.57
▸ ABCG2 Q9UNQ0 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ TUBB1 Q9H4B7 1/20 0.52
▸ CTSB P07858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31233118 1.00 MEN1 (0.79) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL25201055 1.00 MEN1 (0.79) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL30384740 0.92 MEN1 (0.88) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL25201192 0.92 MEN1 (0.88) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL30384858 0.90 MEN1 (0.76) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL25185030 0.90 MEN1 (0.76) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL30383756 0.88 KMT2A (1.00) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL25191765 0.88 KMT2A (1.00) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL25204454 0.87 MEN1 (0.64) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL30383984 0.87 MEN1 (0.64) MEN1KMT2AALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885ALDH1A1 3285/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885ALDH1A1 3081/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885ALDH1A1 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback